
Zymeworks Inc.
Nasdaq · Pharmaceutical Preparations
Company Overview
A concise company profile alongside the latest public filing activity.
Zymeworks Inc. is a clinical-stage biopharmaceutical company that designs and develops multifunctional biotherapeutics, including bispecific antibodies and antibody-drug conjugates, primarily for the treatment of cancer. It uses its proprietary protein engineering platforms to create drug candidates both for its own pipeline and through partnerships with other pharmaceutical companies.
Company profile sourced from SEC filings.
Corporate Insider Trades
Open-market purchases and sales by directors, officers, and other company insiders.
| Insider | Type | Value | Shares / Price | Date |
|---|---|---|---|---|
| Schayowitz AdamEVP, Head of R&D | Sell | $358K | 13,832at $25.85 | Oct 9, 2026 |
Source: SEC EDGAR Form 4 filings
Congressional Trades
Recent disclosures by members of the U.S. House and Senate.
Source: Senate eFD and House Clerk STOCK Act disclosures
Get notable ZYME activity by email
Free alerts for the insider and congressional trades worth watching.
For informational purposes only, not investment advice. Filings can be delayed, corrected, or amended. Trading activity alone does not predict future performance.